Company: APM
Filing Date: 2025-07-15
Form Type: DRS
Source: 0001213900-25-063906
Chunk: 300

Company: Aptorum Group Ltd
Filing Date: 2025-07-15
Form: DRS
Chunk 300
---
 support fund raising and financial statement preparation and audit. In the years ended May 31, 2024 and 2023, DiamiR recognized $1,319,531 and $1,128,002 of grant revenue, respectively, offsetting research and development expenditures. As of May 31, 2024, DiamiR was eligible to receive up to $0.5 million of additional funding under the CRP award through August 2025 to support qualified research and development expenses under the grant, subject to availability of funds and satisfactory progress, as determined by the NIH. DiamiR expects net cash used in operating activities to increase significantly in future periods as a result of unfunded research and development expenses.

174 Financing Activities Net cash provided by financing activities was $200,000 for the year ended May 31, 2024, representing proceeds from a founder loan. Net cash provided by financing activities for the year ended May 31, 2023, was from proceeds received from issuing common stock to one of DiamiR’s founders. There are no agreements with the founders with regard to any future financing. Funding Requirements DiamiR has not completed development of any of its product candidates. DiamiR expects to continue to incur operating losses through at least fiscal 2026. Subject to receiving additional financing, it anticipates that its expenses will increase substantially due to: •continued development of CogniMIR ®; •increased development activities for pipeline projects; •expanded laboratory facilities; and •Additions to operational, financial and management information systems and personnel, including personnel to support DiamiR’s product development, and planned commercialization efforts. DiamiR expects that its existing cash and cash equivalents, and anticipated interest income, will not enable it to complete its development of CogniMIR ®. DiamiR’s forecast of the period of time through which its financial resources will be adequate to support its operations is a forward -lookingstatement and involves risks and uncertainties, and actual results could vary as a result of a number of factors, including the factors discussed in the section entitled “Risk Factors” and elsewhere in this proxy statement/prospectus. DiamiR has based this estimate on assumptions that may prove to be wrong, and it could utilize its available capital resources sooner than currently expected. DiamiR’s future funding requirements, both near- and long -term, will depend on many factors, including, but not limited to: •the initiation, progress, timing, costs, and results of clinical